<DOC>
	<DOCNO>NCT01161264</DOCNO>
	<brief_summary>Influenza pose significant threat individual public health , influenza vaccination trivalent inactivate influenza vaccine widely recommend child , adult risk elderly . Due antigenic change influenza virus , virus strain use interpandemic influenza vaccine adjust every year accord WHO ( World Health Organization ) CHMP ( Committee Medicinal Products Human Use ) recommendation . Following change vaccine antigen composition recommendation previous season , immunogenicity tolerability newly compose vaccine subject evaluation annual clinical trial non-elderly adult elderly subject accord guideline set EMEA ( CPMP/BWP/214/96 ) .</brief_summary>
	<brief_title>Safety Immunogenicity Influenza Vaccine ( Surface Antigen , Inactivated ) Ph.Eur , Formulation 2010/2011 , When Administered Adult Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Male female volunteer 18 year age old , mentally competent , willing able give write informed consent prior study entry ; 2 . Individuals able comply study requirement ; 3 . Individuals good health determine medical history , physical examination clinical judgment investigator . 1 . Individuals behavioral cognitive impairment psychiatric disease , opinion investigator , may interfere subject 's ability participate study ; 2 . Individuals serious chronic acute disease ( judgment investigator ) , include limited : 1 . Cancer , except localize skin cancer ; 2 . Advanced congestive heart failure ; 3 . Chronic obstructive pulmonary disease ( COPD ) ; 4 . Autoimmune disease ( include rheumatoid arthritis ) ; 5 . Acute progressive hepatic disease ; 6 . Acute progressive renal disease ; 7 . Severe neurological psychiatric disorder ; 8 . Severe asthma ; 3 . Individuals history anaphylactic reaction and/or serious allergic reaction follow vaccination , proven hypersensitivity component study vaccine ( e.g . ovalbumin , chicken protein , chicken feather , influenza viral protein , polymyxin , neomycin ) ; 4 . Individuals know suspect ( high risk develop ) impairment/alteration immune function ( exclude normally associate advanced age ) resulting , example , : 1. receipt immunosuppressive therapy ( parenteral oral corticosteroid cancer chemotherapy/radiotherapy ) within past 60 day full length study ; 2. receipt immunostimulants ; 3. receipt parenteral immunoglobulin preparation , blood product and/or plasma derivates within past 3 month full length study ; 4. suspect know HIV infection HIVrelated disease ; 5 . Individuals know suspected history drug alcohol abuse ; 6 . Individuals bleed diathesis condition associate prolonged bleeding time investigator 's opinion would interfere safety subject ; 7 . Female pregnant nursing ( breastfeed ) mother females childbearing age plan use acceptable birth control measure , duration study . Adequate contraception define hormonal ( e.g. , oral , injection , transdermal patch , implant , cervical ring ) , barrier ( e.g. , condom spermicide diaphragm spermicide ) , intrauterine device ( IUD ) , monogamous relationship vasectomize partner vasectomize 6 month prior subject 's study entry ; 8 . Individuals able comprehend follow require study procedure whole period study ; 9 . Individuals within past 12 month receive one injection influenza vaccine ; 10 . Individuals within past 6 month : 1. laboratory confirm seasonal pandemic influenza disease ; 2. receive seasonal pandemic influenza vaccine ; 11 . Individuals acute chronic infection require systemic antibiotic treatment antiviral therapy within last 7 day ; 12 . Individuals experience fever ( i.e. , axillary temperature ≥38°C ) within last 3 day intend study vaccination ; 13 . Individuals participate clinical trial another investigational product 4 week prior first study visit intent participate another clinical study time conduct study ; 14 . Individuals receive vaccine within 4 week prior enrollment study planning receive vaccine within 4 week study vaccine ; 15 . Individuals receive blood , blood product and/or plasma derivative parenteral immunoglobulin preparation past 12 week full length study ; 16 . Individuals part study personnel close family member conduct study ; 17 . Individuals history illness , opinion investigator , might interfere result study pose additional risk subject due participation study ; 18 . BMI &gt; 35 kg/m2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Elderly</keyword>
	<keyword>Influenza</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Influenza vaccine</keyword>
</DOC>